Biopharma company UCB is beating out its competitors when it comes to customer experience (CX) among healthcare professionals (HCP), according to a recent survey out of DT Consulting, an Indegene ...

UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma ...

After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels. This year, the company is focused on growing its blockbuster hopeful Bimzelx and tacking on four extra ...

CHARLOTTE, N.C., October 01, 2025--(BUSINESS WIRE)--UCB Pharma and Tanner Pharma Group today announced they have initiated a partnership in Southeast Asia to enable access to innovative treatments for ...

How do high-priced mergers and acquisitions get done in the biopharmaceutical industry? In filing a 14D-9 with the Securities and Exchange Commission (SEC), Zogenix of California provided an ...

Belgium (21st March, 2003) - New pre-clinical data presented today at the Antiepileptic Drug (AED) VII congress, 20-23rd March, at Key Biscayne, in Florida, U.S.A, reveal a new AED candidate, ucb ...

European biopharmaceutical company UCB SA (OTC:UCBJF) (OTC:UCBJY) announced a $680 million strategic divestment deal in China. The transaction involves the sale, divestment, and license of UCB’s ...

PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design and UCB, a global biopharma company focusing on neurology and immunology, today announced a software ...

UCB S.A. (UCB.BT) will acquire U.S.-based Ra Pharmaceuticals Inc. (RARX) for $2.1 billion in an all cash deal. Shareholders of Ra Pharma will receive $48 for each share held, a joint statement by the ...

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced an agreement to be acquired by Belgian biopharma UCB for $48 per share in cash or $2.5 billion in total. The boards of both companies approved the ...

Belgian drug maker UCB said Wednesday that it is expanding its portfolio of epilepsy treatments by acquiring Zogenix, a U.S.-based biotech with an approved drug for rare childhood seizures, for as ...